Dacomitinib Impurities

Dacomitinib is used for the:

• First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that have EGFR exon 19 deletion or exon 21 L858R substitution mutations
• It helps block tumor growth and prolong progression-free survival in patients with EGFR-positive lung cancer.

• In clinical trials, Dacomitinib showed superior progression-free survival (PFS) compared to gefitinib.
• The ARCHER 1050 trial demonstrated a median PFS of 14.7 months with Dacomitinib versus 9.2 months with gefitinib.
• While effective, it may have higher rates of side effects (e.g., rash, diarrhea), which should be managed proactively.

• Dacomitinib irreversibly binds to the tyrosine kinase domain of the EGFR (ErbB1), as well as HER2 and HER4, inhibiting phosphorylation and downstream signaling.
• This action blocks cellular proliferation and induces apoptosis in EGFR-mutated cancer cells.

• Yes, Dacomitinib was approved by the U.S. FDA in September 2018.
• It is approved specifically for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations.